| Vasopressin | Par Pharma | ||
| 20 units/mL; Solution, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Indicated to increase blood pressure in adults with vasodilatory shock (e.g., postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. | |||
|
Yes
| |||
| Vasostrict | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
|---|---|---|---|---|---|---|---|
| ***** | ********* | ********* | *** ** ** (*** **********) | ********* | *** ** ** (*** **********) | ********* | ********* |
| ******* ****** | ******* | ******* | ******* | ******* | ******* | ******* | **** ** *** *, **** |
| ****** | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ********* | *** **, **** | *** ** ** | ******** | ******** '**-****' ** *** **, **** |
| ******* ****** | ** \ ** | ** | ******* | **** | ******** ********** *********** ** *** **, **** |
| ****** | ** \ ** | *** *, **** | ******* | **** | ****** **** ******** |
| Vasopressin | Par sterile products | ||
| 40 units/100 mL and 60 units/100 mL ; Solution, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| None | |||
|
No
| |||
| Vasostrict | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | *** ********* |
| ****** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** / ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
| ****** | ***(*)(*) | -**- | ******* | **** | *** ***** ** ******* |
| Vasopressin | Par sterile products | ||
| 20 units/100 mL; Solution, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
|
Less Than 5
|
None | ||
| Vasostrict is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines | |||
|
Yes
| |||
| Vasostrict | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | *** ********* |
| ****** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ *** | *** **, **** | ******* | ******** | ******* *** **** *** *** **** |
| ****** | ***(*)(*) | -**- | ******* | **** | *** ***** ** ******* |
| Vasopressin | Par Pharma | ||
| 200 units/10 mL; Solution, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| Indicated to increase blood pressure in adults with vasodilatory shock (e.g., postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. | |||
|
Yes
| |||
| Vasostrict | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| ****** | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ****** | *** ********* | *** ********* | ******* | *** ********* | ******* | *** ********* | ******* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ********* **** | ******* | ******* | ******* | ******* ***** *** ** ** | ******* | ******* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ *** | *** *, **** | ******* | **** | ****** **** ******** |
| ****** | ** \ ** | *** **, **** | ******* | ********* ******** | ***** ***-**** *********** |
| ********* **** | ** \ ** | *** **, **** | ******* ***** *** ** ** ** ****** '*** | ********* ******** | ***** ***-**** *********** |
Download ParaIV Report